Gesellschaftsrecht / M&A

Finanzierungen und Anlageprodukte

Wettbewerb

Regulierung

Vencora_webnews

Homburger News

Homburger and Vencora UK Limited

On February 22, 2024, Vencora UK Limited (Vencora), an indirect subsidiary of Volaris Group Inc. and Constellation Software Inc. (CSI), a Canadian-based international provider of software and services (TSX: CSU), announced that its all-cash public tender offer for all publicly held shares of Crealogix Holding AG (Crealogix) has been settled and that the share purchase agreement between certain shareholders of Crealogix and Vencora for the sale of a total of 51.66% of all shares in Crealogix to Vencora has been consummated. As a result, Vencora has acquired a 99.07% stake in Crealogix.
Homburger AG has advised Vencora and CSI on the transaction. The Homburger team is led by Daniel Hasler and comprises Micha Fankhauser, Carlo Sulser, Léonard Aeschlimann Perales, Oliver Kneubühl, Matthias Müller, Caroline Grand and Thomas Waidacher (all Corporate / M&amp;A), Benjamin Leisinger and Manuel Baschung (both Financing and Investment Products), Richard Stäuber and Christoph Grüninger (both Competition, Regulatory).

Homburger has advised Vencora UK Limited on the settlement of its public tender offer for all publicly held shares of Crealogix Holding AG and on the consummation of the share purchase agreement with certain Crealogix shareholders

IP / IT

Arbeitsrecht und Vergütung für Führungskräfte

Homburger and Vencora and Constellation Software Inc.

On November 16, 2023, Vencora UK Limited, an indirect subsidiary of Volaris Group Inc. and Constellation Software Inc. (CSI), a Canadian-based international provider of software and services (TSX: CSU), and Crealogix Holding AG, a Swiss-based global leader in digital banking technology (SIX: CLXN), jointly announced that they have entered into a definitive transaction agreement, under which Vencora agreed to submit an all-cash public tender offer to acquire all publicly held registered shares of Crealogix for CHF 60 per share, for an aggregate equity value for Crealogix of approximately CHF 84 m. Vencora published its pre-announcement of the offer today. Certain shareholders of Crealogix have concurrently entered into a share purchase agreement with Vencora for the sale of a total of 51.66% of all shares in Crealogix to Vencora.
The offer and the share purchase agreement with the selling shareholders are conditional upon the receipt of regulatory clearances in certain jurisdictions and other customary conditions.
Homburger AG advises Vencora and CSI on the transaction. The Homburger team is led by Daniel Hasler (Corporate / M&amp;A) and comprises Micha Fankhauser, Carlo Sulser, Léonard Aeschlimann Perales, Oliver Kneubühl, Thierry Burckhardt, Héloïse De Jamblinne, Aron Belegu, Thomas Waidacher, Jana Waldvogel and Sabrina Vieli (all Corporate / M&amp;A), Manuel Baschung (Financing and Investment Products), Richard Stäuber and Christoph Grüninger (both Competition, Regulatory), Joel Fink (IP / IT) and Giulia Menegon (Employment and Executive Compensation).

Homburger advises Vencora UK Limited, an indirect subsidiary of Volaris Group Inc. and Constellation Software Inc., with respect to its announced public tender offer for all publicly held shares of Crealogix Holding AG

Kapitalmarkt

Steuern

Datenschutz

Healthcare / Life Sciences

Vectivio

Homburger and VectivBio

On May 22, 2023, VectivBio Holding AG (Nasdaq: VECT), Basel (Switzerland), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare gastrointestinal conditions, and Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced that they had entered into an agreement for Ironwood to launch an all-cash public tender offer to acquire all outstanding shares in VectivBio for USD 17 per share, with an estimated aggregate consideration of approximately USD 1 bn, net of VectivBio cash and debt. The acquisition price represents a premium of 80% relative to the volume-weighted average share price over the previous 90 trading days. The offer is subject to customary conditions and expected to close in mid-2023. VectivBio&#8217;s board of directors unanimously recommends the offer. Orbimed, Forbion and Versant Ventures, and VectivBio&#8217;s directors and officers jointly representing 28.6% of VectivBio&#8217;s shareholdings, entered into tender and support agreements in connection with, and in support of, the offer.
Homburger AG serves as legal and tax advisor to VectivBio on the transaction. The Homburger team includes Andreas Müller, Margrit Marti, Oliver Kneubühl, Francesco Bernasconi, Oliver Dalla Palma, Daniel Wenzinger and Carolina Rodriguez (all Corporate / M&amp;A), Lorenzo Togni (Capital Markets), Stefan Oesterhelt, Philippe Gobet and Kevin Müller (all Tax), Stefan Bindschedler (Financing and Investment Products), Luca Dal Molin (IP / IT; Data Protection), Angela Casey (Employment and Executive Compensation), and Richard Stäuber and Christoph Grüninger (Competition, Regulatory).

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Oliver
Kneubühl

Homburger has advised Vencora UK Limited on the settlement of its public tender offer for all publicly held shares of Crealogix Holding AG and on the consummation of the share purchase agreement with certain Crealogix shareholders

Homburger advises Vencora UK Limited, an indirect subsidiary of Volaris Group Inc. and Constellation Software Inc., with respect to its announced public tender offer for all publicly held shares of Crealogix Holding AG

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Karriere

Sprachen

Teams

OliverKneubühl

Homburger has advised Vencora UK Limited on the settlement of its public tender offer for all publicly held shares of Crealogix Holding AG and on the consummation of the share purchase agreement with certain Crealogix shareholders

Homburger advises Vencora UK Limited, an indirect subsidiary of Volaris Group Inc. and Constellation Software Inc., with respect to its announced public tender offer for all publicly held shares of Crealogix Holding AG

Homburger advises VectivBio with respect to the announced public cash tender offer from Ironwood Pharmaceuticals

Swissair: Pflichtgemässe Verletzung von Kapitalschutzvorschriften?

Join the Team

Oliver Kneubühl

Karriere

Sprachen

Teams

Oliver
Kneubühl